人工晶状体表面改性抑制后发性白内障的研究进展

doi:10.3760/cma.j.cn115909-20190521-00146

Abstract
Figure/Table
References (57)
Related Citation (15)

Download: PDF (721 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cataract is the main cause of blinding diseases. Phacoemulsification combined with intraocular lens (IOL) implantation is a commonly used clinical treatment. Visual acuity recovers well after the operation. However, since the IOL is an extrinsic implant, a high incidence of complications may occur postoperatively. In addition to acute inflammation, long-term in vivo biocompatibility problems-posterior capsular opacification (PCO, which is also called a secondary cataract) may occur over time and decrease vision again. The improvement of surgical methods and the design and processing of the IOL can reduce the incidence of PCO. However, PCO still occurs due to the intrinsic compatibility of the IOL materials. This review summarizes the IOL surface modifications used to inhibit PCO from the perspective of the science of materials.

Key words： intraocular lens surface modification posterior capsular opacification biomaterial

Received: 21 May 2019

Fund:National Key R & D Program (2017YFC1104602); National Natural Science Foundation of China (31570959); Medical & Health Technology Program of Zhejiang Province (2018KY540); Basic Scientific Program of Wenzhou (Y20180170)

Corresponding Authors: Quankui Lin, Eye hospital, Wenzhou Medical University, Wenzhou 325027, China (Email: linqk@wmu.edu.cn)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.cn115909-20190521-00146 OR https://www.cjoovs.com/EN/Y2020/V22/I8/630

[1]	Wormstone IM. Posterior capsule opacification: A cell biological perspective. Exp Eye Res, 2002, 74(3): 337-347. DOI: 10.1006/ exer.2001.1153.
[2]	Wu S, Tong N, Pan L, et al. Retrospective analyses of potential risk factors for posterior capsule opacification after cataract surgery. J Ophthalmol, 2018, 9089285. DOI: 10.1155/2018/9089285.
[3]	R?kas M, Klu? A, Kosatka M. Sealed-capsule irrigation with distilled deionized water to prevent posterior capsule opacification-prospective, randomized clinical trial. Curr Eye Res, 2013, 38(3): 363-370. DOI: 10.3109/02713683.2012. 748079.
[4]	Bertrand V, Bozukova D, Svaldo Lanero T, et al. Biointerface multiparametric study of intraocular lens acrylic materials. J Cataract Refract Surg, 2014, 40(9): 1536-1544. DOI: 10.1016/ j.jcrs.2014.01.035.
[5]	Iliescu IM, Constantin MA, Cozma C, et al. Posterior Capsule Opacification and Nd-YAG rates evaluation in a large series of pseudophakic cases. Rom J Ophthalmol, 2017, 61(4): 267-274.
[6]	Trivedi RH, Werner L, Apple DJ, et al. Post cataract-intraocular lens (IOL) surgery opacification. Eye (Lond), 2002, 16(3): 217- 241. DOI: 10.1038/sj.eye.6700066.
[7]	Pandey SK, Werner L, Apple DJ, et al. Hydrophilic acrylic intraocular lens optic and haptics opacification in a diabetic patient: Bilateral case report andclinicopathologic correlation. Ophthalmology, 2002, 109(11): 2042-2051. DOI: 10.1016/ s0161-6420(02)01265-4.
[8]	曲超, 姚克, 寇瑞强, 等. α-烯丙基葡糖苷对聚甲基丙烯酸甲酯人工晶状体的表面修饰. 生物医学工程学杂志, 2004, 21(1): 115-117. DOI: 10.3321/j.issn.1001-5515.2004.01.029.
[9]	李娜, 王桂琴, 曹利群, 等. 单面修饰疏水性人工晶状体表面细胞黏附实验研究. 国际眼科杂志, 2014, 14(3): 419-421. DOI: 10.3980/j.issn.1672-5123.2014.03.10.
[10]	王桂琴, 顾汉卿, 彭秀军. 人工晶状体表面修饰技术研究.眼科研究, 2007, 25(8): 627-628. DOI: 10.3760/cma.j.issn.2095- 0160.2007.08.018.
[11]	王桂琴, 曹利群, 李娜, 等. 表面修饰疏水性丙烯酸酯人工晶状体表面超微结构的观察. 眼科新进展, 2014, 34(10): 904- 906. DOI: 10.13389/j.cnki.rao.2014.0250.
[12]	Viveiros MM, Soares RT, Omodei MS, et al. Adhesion study of cultured human lens capsule cells on hydrophilic intraocular lenses coated with polyethylene glycol. J Cataract Refract Surg, 2015, 41(7): 1478-1483. DOI: 10.1016/j.jcrs.2014.11.047.
[13]	Lin L, Wang Y, Huang XD, et al. Modification of hydrophobic acrylic intraocular lens with poly (ethylene glycol) by atmospheric pressure glow discharge: A facile approach. Appl Surf Sci, 2010, 256(24): 7354-7364. DOI: 10.1016/ j.apsusc.2010.05.068.
[14]	Xu X, Tang JM, Han YM, et al. Surface PEGylation of intraocular lens for PCO prevention: An in vivo evaluation. J Biomater Appl, 2016, 31(1): 68-76. DOI: 10.1177/0885328216638547.
[15]	Tang J, Han Y, Chen H, et al. Bottom-up fabrication of PEG brush on Poly (dimethylsiloxane) for antifouling surface construction. 2016, 8458752. DOI: 10.1155/2016/8458752.
[16]	Lin Q, Tang J, Han Y, et al. Hydrophilic modification of intraocular lens via surface initiated reversible additionfragmentation chain transfer polymerization for reduced posterior capsular opacification. Colloids Surf B Biointerfaces, 2017, 151: 271-279. DOI: 10.1016/j.colsurfb.2016.12.028.
[17]	许利娜, 马培培, 陈强, 等. 甲基丙烯酰乙基磺基甜菜碱类聚合物的生物应用. 化学进展, 2014, 26(2): 366-374. DOI: 10.7536/PC130839.
[18]	Han Y, Xu X, Tang J, et al. Bottom-up fabrication of zwitterionic polymer brushes on intraocular lens for improved biocompatibility. Int J Nanomedicine, 2017, 12: 127-135. DOI: 10.2147/IJN.S107491.
[19]	Huang X, Luo C, Lin L, et al. UV-assisted treatment on hydrophobic acrylic IOLs anterior surface with methacryloyloxyethyl phosphorylcholine: Reducing inflammation and maintaining low posterior capsular opacification properties. Mater Sci Eng C Mater Biol Appl, 2017, 75: 1289-1298. DOI: 10.1016/j.msec.2017.03.029.
[20]	Tan X, Zhan J, Zhu Y, et al. Improvement of uveal and capsular biocompatibility of hydrophobic acrylic intraocular lens by surface grafting with 2-methacryloyloxyethyl phosphorylcholine-methacrylic acid copolymer. Sci Rep, 2017, 7: 40462. DOI: 10.1038/srep40462.
[21]	?zyol P, ?zyol E, Karel F. Biocompatibility of intraocular lenses. Turk J Ophthalmol, 2017, 47(4): 221-225. DOI: 10.4274/ tjo.10437.
[22]	Yoo PJ, Nam KT, Qi J, et al. Spontaneous assembly of viruses on multilayered polymer surfaces. Nat Mater, 2006, 5(3): 234- 240. DOI: 10.1038/nmat1596.
[23]	Wang GQ, Gu HQ, Yuan JQ, et al. F-heparin modified intraocular lenses in Rhesus monkeys. Int J Ophthalmol, 2010, 3(2): 141-144. DOI: 10.3980/j.issn.2222-3959.2010.02.11.
[24]	Krall EM, Arlt EM, Jell G, et al. Intraindividual aqueous flare comparison after implantation of hydrophobic intraocular lenses with or without a heparin-coated surface. J Cataract Refract Surg, 2014, 40(8): 1363-1370. DOI: 10.1016/j.jcrs.2013.11.043.
[25]	Krall EM, Arlt EM, Jell G, et al. Prospective randomized intraindividual comparison of posterior capsule opacification after implantation of an IOL with and without heparin surface modification. J Refract Surg, 2015, 31(7): 466-472. DOI: 10.3928/1081597x-20150623-05.
[26]	Wang B, Lin Q, Jin T, et al. Surface modification of intraocular lenses with hyaluronic acid and lysozyme for the prevention of endophthalmitis and posterior capsule opacification. RSC Adv, 2014, 5(5): 3597-3604. DOI: 10.1039/C4RA13499K.
[27]	刘苗苗. 低分子壳聚糖对人晶状体上皮细胞CLC-3的表达及功能影响. 吉林: 吉林大学, 2015.
[28]	Lin Q, Xu X, Wang B, et al. Hydrated polysaccharide multilayer as an intraocular lens surface coating for biocompatibility improvements. J Mater Chem B, 2015, 3(18): 3695-3703. DOI: 10.1039/C5TB00111K.
[29]	Kim SY, Kim JH, Choi JS, et al. Comparison of posterior capsule opacification in rabbits receiving either mitomycin-C or distilled water for sealed-capsule irrigation during cataract surgery. Clin Exp Ophthalmol, 2007, 35(8): 755-758. DOI: 10.1111/j.1442-9071.2007.01588.x.
[30]	Bretton RH, Swearingen A, Kash RL, et al. Use of a polylysinesaporin conjugate to prevent posterior capsule opacification. J Cataract Refract Surg, 1999, 25(7): 921-929. DOI: 10.1016/ S0886-3350(99)00076-0.
[31]	Wu M, Li H, Li S, et al. The effect of liposome encapsulated daunorubicin on rabbit eyes after extracapsular lens extraction. Eye Sci, 2000, 16(3): 189-193.
[32]	Legler UF, Apple DJ, Assia EI, et al. Inhibition of posterior capsule opacification: The effect of colchicine in a sustained drug delivery system. J Cataract Refract Surg, 1993, 19(4): 462-470. DOI: 10.1016/S0886-3350(13)80609-8.
[33]	Totan Y, Ya?ci R, Erdurmu? M, et al. Cyclosporin effectively inhibits posterior capsule opacification after phacoemulsification in rabbits: A preliminary study. Clin Exp Ophthalmol, 2008, 36(1): 62-66. DOI: 10.1111/j.1442-071.2007.01653.x.
[34]	Theng JT, Ti SE, Zhou L, et al. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest Ophthalmol Vis Sci, 2003, 44(11): 4895-4899. DOI: 10.1167/iovs.02-1112.
[35]	Pei C, Xu Y, Jiang JX, et al. Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits. Int J Ophthalmol, 2013, 6(1): 1-7. DOI: 10.3980/j.issn.2222-3959.2013.01.01.
[36]	Guha R, Chowdhury S, Palui H, et al. Doxorubicin-loaded MePEG-PCL nanoparticles for prevention of posterior capsular opacification. Nanomedicine (Lond), 2013, 8(9): 1415-1428. DOI: 10.2217/nnm.12.175.
[37]	Huang X, Wang Y, Cai JP, et al. Sustained release of 5-fluorouracil from chitosan nanoparticles surface modified intra ocular lens to prevent posterior capsule opacification: An in vitro and in vivo study. J Ocul Pharmacol Ther, 2013, 29(2): 208-215. DOI: 10.1089/jop.2012.0184.
[38]	Kassumeh SA, Wertheimer CM, von Studnitz A, et al. Poly (lactic-co-glycolic) acid as a slow-release drug-carrying matrix for methotrexate coated onto intraocular lenses to conquer posterior capsule opacification. Curr Eye Res, 2018: 43(6): 1-7. DOI: 10.1080/02713683.2018.1437455.
[39]	Han Y, Xu X, Wang Y, et al. Drug Eluting Intraocular Lens Surface Modification for PCO Prevention. 2018, 24: 40-44. DOI: 10.1016/j.colcom.2018.03.007.
[40]	Liu H, Wu L, Fu S, et al. Polylactide-glycoli acid and rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes. Graefes Arch Clin Exp Ophthalmol, 2009, 247(6): 801-807. DOI: 10.1007/s00417-008-1007-0.
[41]	Liu H, Zhang Y, Ma H, et al. Comparison of posterior capsule opacification in rabbit eyes receiving different administrations of rapamycin. Graefes Arch Clin Exp Ophthalmol, 2014, 252(7): 1111-1118. DOI: 10.1007/s00417-014-2656-9.
[42]	Kampmeier J, Baldysiak-Figiel A, de Jong-Hesse Y, et al. Effect of growth factors on proliferation and expression of growth factor receptors in a human lens epithelial cell line. J Cataract Refract Surg, 2006, 32(3): 510-514. DOI: 10.1016/ j.jcrs.2005.08.063.
[43]	Majima K. Human lens epithelial cells proliferate in response to exogenous EGF and have EGF and EGF receptor. Ophthalmic Res, 1995, 27(6): 356-365. DOI: 10.1089/jop.2006.22.93.
[44]	Jiang Q, Zhou C, Bi Z, et al. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther, 2006, 22(2): 93- 102. DOI: 10.1089/jop.2006.22.93.
[45]	Wertheimer C, Liegl R, Kernt M, et al. EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification. Graefes Arch Clin Exp Ophthalmol, 2013, 251(6): 1529-1540. DOI: 10.1007/s00417-013-2257-z.
[46]	Wertheimer C, Liegl R, Kernt M, et al. EGFR-blockade with erlotinib reduces EGF and TGF-β2 expression and the actincytoskeleton which influences different aspects of cellular migration in lens epithelial cells. Curr Eye Res, 2014, 39(10): 1000-1012. DOI: 10.3109/02713683.2014.888453.
[47]	Wertheimer C, Kueres A, Siedlecki J, et al. The intraocular lens as a drug delivery device for an epidermal growth factorReceptor inhibitor for prophylaxis of posterior capsule opacification. Acta Ophthalmol, 2018, 96(7): e874-874e882. DOI: 10.1111/aos.13759.
[48]	Wertheimer C, Siedlecki J, Kook D, et al. EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model. Graefes Arch Clin Exp Ophthalmol, 2015, 253(3): 409-417. DOI: 10.1007/s00417- 014-2875-0.
[49]	Lin L, Lin Q, Li J, et al. ROCK inhibitor modified intraocular lens as an approach for inhibiting the proliferation and migration of lens epithelial cells and posterior capsule opacification. Biomater Sci, 2019, 7(10): 4208-4217. DOI: 10.1039/c9bm00787c.
[50]	Dawes LJ, Angell H, Sleeman M, et al. TGFbeta isoform dependent Smad2/3 kinetics in human lens epithelial cells: A Cellomics analysis. Exp Eye Res, 2007, 84(5): 1009-1012. DOI: 10.1016/j.exer.2006.12.017.
[51]	Wormstone IM, Anderson IK, Eldred JA, et al. Short-term exposure to transforming growth factor beta induces long-term fibrotic responses. Exp Eye Res, 2006, 83(5): 1238-1245. DOI: 10.1016/j.exer.2006.06.013.
[52]	Zhang Z, Zhu H, Liu Y, et al. LncRNA HOTAIR mediates TGFbeta2-induced cell growth and epithelial-mesenchymal transition in human lens epithelial cells. Acta Biochim Biophys Sin, 2018, 50(10): 1028-1037. DOI: 10.1093/abbs/gmy101.
[53]	Sun CB, Teng WQ, Cui JT, et al. The effect of anti-TGF-β2 antibody functionalized intraocular lens on lens epithelial cell migration and epithelial-mesenchymal transition. Colloids Surf B Biointerfaces, 2014, 113: 33-42. DOI: 10.1016/ j.colsurfb.2013.08.024.
[54]	Yang Y, Ye Y, Lin X, et al. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlialmesenchymal transition of human lens epithelial cells line SRA01/04. PLoS One, 2013, 8(2): e56837. DOI: 10.1371/ journal.pone.0056837.
[55]	Shao JZ, Qi Y, Du SS, et al. In vitro inhibition of proliferation, migration and epithelial-mesenchymal transition of human lens epithelial cells by fasudil. Int J Ophthalmol, 2018, 11(8): 1253- 1257. DOI: 10.18240/ijo.2018.08.02.
[56]	刘冬梅, 李俊红. 基质金属蛋白酶及其抑制剂与后发性白内障发生的关系. 中华眼视光学与视觉科学杂志, 2016, 18(9): 565-568. DOI: 10.3760/cma.j.issn.1674-845X.2016.09.014.
[57]	Hazra S, Guha R, Jongkey G, et al. Modulation of matrix metalloproteinase activity by EDTA prevents posterior capsular opacification. Mol Vis, 2012, 18: 1701-1711. DOI: 10.1111/ j.1475-1313.2012.00927.x.